Callisto Executives Discuss Newly Licensed Anti-Cancer Drug Class Degrasyns in Interview with BiomedDiscoveries.com; Degrasyns' Novel Tumor-Fighting Mechanism Significantly Broadens Company's Drug Development Pipeline.

LOS ANGELES -- BiomedDiscoveries.com, http://www.BiomedDiscoveries.com, the online source for exclusive investor information in the biotechnology sector, announced today the availability of a new Q&A interview with executives of Callisto Pharmaceuticals Inc. (AMEX:KAL)(FWB:CA4), a developer of new drug therapies in the fight against cancer and other serious health threats. In the written interview, the Callisto executives discuss the Company's recently announced exclusive licensing of a new drug class called Degrasyn, whose novel activity is designed to attack a wide range of cancer tumors.

Degrasyns has been shown to selectively degrade key proteins involved in tumor cell proliferation and survival. The new drug class was developed at the world-renowned University of Texas M.D. Anderson Cancer Center, and has now been licensed to Callisto for further clinical development, in cooperation with M.D. Anderson.

"Our recent acquisition of the licensing rights to Degrasyns significantly broadens Callisto's drug development pipeline, extending our portfolio of anticancer drug candidates well beyond our previous focus on blood cancers to a very large category of solid tumor cancers," said Dr. Gary S. Jacob, CEO and Chief Scientific Officer of Callisto. "We anticipate developing this compound further which will strengthen our commitment to deliver breakthrough anti-tumor drugs to the global pharmaceutical industry."

The interview, available free of charge to all interested investors, can be accessed by visiting: http://www.BiomedDiscoveries.com.

About Callisto Pharmaceuticals, Inc.

Callisto is a biopharmaceutical company focused on the development of new drugs to treat various forms of cancer and other serious afflictions. Callisto's drug candidates in development currently include anti-cancer agents in clinical development, in addition to drugs for a range of other significant health care market segments, including biodefense. One of the Company's lead drug candidates, L-Annamycin, is being developed as a treatment for forms of relapsed leukemia, a currently incurable blood cancer. Callisto initiated a clinical trial of L-Annamycin in relapsed acute lymphoblastic leukemia patients in 4Q 2005. L-Annamycin, a new compound from the anthracycline family of proven anti-cancer drugs, has a novel therapeutic profile, including activity against resistant diseases and significantly reduced cardiotoxicity, or damage to the heart, compared to currently available drug alternatives. Another anti-cancer drug, Atiprimod, is in development to treat relapsed multiple myeloma, a blood cancer. Atiprimod has entered Phase I/IIa human clinical trials in relapsed multiple myeloma patients. Callisto also has drugs in preclinical development for gastrointestinal inflammation, and a program focused on the development of a drug to protect against staphylococcus and streptococcus biowarfare agents. Callisto has exclusive worldwide licenses from AnorMED Inc. and M.D. Anderson Cancer Center to develop, manufacture, use and sell Atiprimod and L-Annamycin, respectively. For investor-specific information about Callisto, including recent news and stock price data, please visit http://www.trilogy-capital.com/tcp/callisto/. For an Investor Fact Sheet about Callisto, please visit http://www.trilogy-capital.com/tcp/callisto/factsheet.html. To view an informational presentation of the Company's development pipeline of drug candidates, visit http://www.trilogy-capital.com/tcp/callisto/powerpoint.html. Callisto is also listed on the Frankfurt Stock Exchange under the ticker symbol CA4. For additional information, visit www.callistopharma.com.

About BiomedDiscoveries.com

BiomedDiscoveries.com provides exclusive commentary, research, interviews and other information about the smallcap investment marketplace. BiomedDiscoveries.com strives to provide investors with information and research-based data regarding important individual companies and overall marketplace trends. Resources available on BiomedDiscoveries.com include audio interviews with corporate leaders and respected commentators, as well as technical white papers and other forms of market and investment analysis. It is located at http://www.BiomedDiscoveries.com.

Forward-Looking Statements

Statements made on BiomedDiscoveries.com may contain forward-looking statements made by senior management of the companies presented here that involve risks and uncertainties, such as statements about plans, objectives, expectations, assumptions or future events. These statements involve estimates, assumptions, known and unknown risks, uncertainties and performances, or achievements expressed or implied by the forward-looking statements. Actual future results and trends may differ materially from those made in -- or suggested by -- statements presented here due to a variety of factors. Consequently, you should not place undue reliance on any forward-looking statements made here. Many of these and other risks and uncertainties are discussed in greater detail in recent filings with the Securities Exchange Commission for the companies that are presented by BiomedDiscoveries.com.

Compensation and Other Disclosures

BiomedDiscoveries.com is a wholly owned subsidiary of Trilogy Capital Partners, Inc. Trilogy Capital Partners provides investor relations services to public companies. The companies presented by BiomedDiscoveries.com are usually clients of Trilogy Capital Partners and compensate Trilogy Capital Partners for these services, including cash compensation and equity securities. In addition, Trilogy Capital Partners and its affiliates may own securities of the presenting companies, and may from time to time purchase and sell securities of these companies in the open market or in private transactions. Callisto pays $12,500 per month through July 2006 and thereafter for so long as Trilogy is retained to provide investor relations services. In connection with its engagement, Trilogy received non-transferable warrants from this company to purchase 1,793,322 shares of common stock for $1.03 per share expiring in July 2008, provided that the warrants are not exercisable to the extent that following exercise Trilogy would beneficially own 5% or more of the outstanding common stock of the company.